Abstract
Introduction
Spinal tuberculosis is the most common form of skeletal system tuberculosis infection and it has a very high prevalence and morbidity in China [1] . As various anti-tuberculosis drugs poorly permeate foci and cold abscess in the vertebral body and do not always achieve effective therapeutic levels [2] , it is difficult to treat spinal tuberculosis using drugs [3] . With surgery, the tuberculosis foci on which anti-tuberculosis medications are not effective, such as caseous necrotic tissue, abscess and dead bone, can be removed, but the Mycobacterium tuberculosis bacilli cannot be completely cleared. Thus, neither medication nor surgery is completely effective in removing spinal tuberculosis foci in vivo. Thus focus removal and even spinal tuberculosis recurrence are rarely avoided. Therefore, the immunity of the host after spinal tuberculosis surgery has a decisive influence on the patient's clinical prognosis [4] [5] [6] .
During the host's M. tuberculosis-specific immune response, monocyte chemoattractant protein-1 (MCP-1) participates in the inhibition of in vivo dissemination of M. tuberculosis, regulating the secondary immune response.ThereforeMCP-1 is an important promoter and regulator of a host's defense against tuberculosis infection. Our previous findings have shown that MCP-1 gene polymorphisms and serum MCP-1 level greatly influence the occurrence and development of spinal tuberculosis [7] . However, the role and effect of MCP-1 in a host's defense against M. tuberculosis infection after surgery remain poorly understood. To the best of our knowledge, there have been no related reports in the literature. Therefore, we performed a postoperative follow-up observational study to further investigate the effect of MCP-1 serum level on the clinical outcome of spinal tuberculosis after surgery. Patients who had any of the following conditions were rejected for this study: (1) drug-resistant tuberculosis; (2) diseases that influence the immune state, including infection, trauma and tumor; (3) diseases that influence MCP-1 expression, including coronary heart disease and psoriasis; (4) autoimmune diseases; (5) tuberculosis of other organs (or had a history of this disease); (6) hereditary disease; (7) spinal surgery; (8) not receiving the Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine.
Subjects and Methods

Subjects
The study protocol received approval from the Human Ethics Committee, Central South University, China. Written informed consent was obtained from each subject prior to inclusion in the study. The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details.
Methods
After regular anti-tuberculosis treatment, when blood sedimentation was normal or decreased, tuberculosis foci removal together with internal fixation and bone grafting was performed. At 1 and 2 weeks after surgery and during the follow-up period, 5 mL fasting blood was taken from the median cubital vein using a pro-coagulation tube in the morning, shaken slightly, and then centrifuged at 193.587 g (1000 rpm) at 4°C for 10minutes. For the patients who suffered from recurred disease, sample taking was necessary when they came back for treatment, at 1 and 2 weeks after being resolved and during the follow-up period. The supernatant was transferred to a 1.5-mL EppendorfSafe-Lockmicrocentrifuge tube and stored at −80°C. The MCP-1 concentration was determined using a human MCP-1 ELISA kit (Shanghai ExCellBioCo.,Ltd., China) according to manufacturer's recommendations. The optical density was measured at 450nm using a microplate reader (Beckman Coulter, Inc., Brea, CA, USA). Recurrence of spinal tuberculosis after surgery and during the follow-up period was recorded in detail.
Follow-up and observation
The patients without disease recurrence underwent examination with x-ray, CT, MRI and serum MCP-1 levels measured at 3, 6 and 12 months after surgery and then once per year. The patients with disease recurrence underwent examination with x-ray, CT, MRI and serum MCP-1 levels measured immediately after recurrence of spinal tuberculosis. When the disease recurrence was resolved, these patients were asked to undergo the above examinations once every 6 months.
Statistical analysis
All data were statistically analyzed using SPSS 13.0 software(IBM Corp., Armonk, NY, USA). ttests and one-way analysis of variance were used for comparison of MCP-1 concentration between groups. Data was normally distributed and expressed as the mean ± SD. A P-value of P< 0.05 was considered statistically significant.
Results
Patient characteristics
One hundred sixty-nine patients with spinal tuberculosis, consisting of 95 males and 74 females, aged 40.62±17.38 years (range, 2-78 years) were enrolled in the study. Through examination of x-ray, CT and MRI results, the tuberculosis lesions were located in the cervical vertebrae in 11 patients, in the T 1-9 segments in 44 patients, in the T 10 -L 2 segments in 47 patients, in the L 3-5 segments in 51 patients, and in the L 5 -S 1 in 16 patients.
Patient follow-up and complications
All patients were followed for 2.2±1.3 years (range, 1-5 years). Eleven (6.51%) patients had postoperative recurrence of spinal tuberculosis, including fistula (n = 6; Fig 1) , iliopsoas abscess (n = 3; Fig 2) , and bone destruction (n = 2; Fig 3) . Disease recurrence in these patients was resolved after active treatment and had not reoccurred at the last follow-up.
Comparison of serum levels of MCP-1
Serum level of MCP-1 in patients with recurrence of spinal tuberculosis. Serum level of MCP-1 was significantly increased after recurrence of spinal tuberculosis when compared with the previous follow-up (t = 2.463, P = 0.023). When the symptoms of recurrence were resolved, serum level of MCP-1 was significantly decreased at the last follow-up compared with both the period of disease recurrence (t = -5.614, P<0.01) and prior to the onset of recurrence (t = -5.79, P<0.01; Table 1 ). Serum level of MCP-1 in patients with and without disease recurrence. Serum level of MCP-1 was significantly increased in patients who would develop recurrent disease compared with patients without recurrence at follow-up (t = 6.034, P<0.01). When the recurrent disease was resolved, there was no significant difference in serum MCP-1 level at the last follow-up between patients with and without disease recurrence (t = 1.88, P = 0.062; Table 1 ).
Discussion
In patients with spinal tuberculosis, the originally closed vomica will be opened after surgery, which unavoidably results in M. tuberculosis entering into the circulation and triggering a systemic immune response. In addition, after removal of liquor puris and dead bone, the balance between the host's resistance and bacterial virulence will be destroyed. Thus, the host will attack M. tuberculosis, and a large number of inflammatory cells will begin to migrate from the systemic circulation to the focus cavity and phagocytose M. tuberculosis. After using anti-tuberculosis drugs, the host is able to remove any residual M. tuberculosis, resulting in clinical resolution of infection. Therefore, patient immunity is a key factor in reducing postoperative recurrence and influencing the prognosis [8, 9] .
MCP-1 (chemokine (C-C motif) ligand 2, CCL2) is a chemokine involved in Th1 and Th2 immunity and regulates immune cell function [10] . MCP-1 influences the occurrence and development of spinal tuberculosis through various regulatory pathways. Specifically, it can both inhibit the occurrence of spinal tuberculosis and also promote the development of this disease, with the final regulatory result depending on both the time window of MCP-1 expression and the serum level of MCP-1 [11, 12] . There is evidence that the serum level of MCP-1 increases to varying degrees in patients with tuberculosis [13, 14] . Hasan et al [12] confirmed that serum MCP-1 level gradually increases with the aggravation of disease severity in patients with tuberculosis. Furthermore, Su et al. [15] found that the serum level of MCP-1 was more significantly elevated in late tuberculosis responders than in early tuberculosis responders. However it was normal in all patients after resolution of their tuberculosis infections. Our results also showed that the serum level of MCP-1 was significantly increased after the recurrence of spinal tuberculosis, and decreased after the recurrence was cured. Similarly, there were no significant differences in serum MCP-1 level at the last follow-up between patients with and without disease recurrence.
Shigenaga et al [16] showed that in reinfected dermal Calmette-Guérin lesions, MCP-1 levels peaked at 3 hours and were then down-regulated. Sustained overexpression of MCP-1 can initiate a series of adverse events. High levels of MCP-1 will limit monocyte responses and induce transforming growth factor-βexpression, selectively inhibiting Th1 immune responses bydecreasinginterleukin-12 (IL-12) and interferon-γ expression, and also influencing the formation of granuloma [17] . Ganachari et al [18] showed that MCP-1 can increase the expression of matrix metalloproteinase-1 in M. tuberculosis stimulated THP-1 cells. Matrix metalloproteinase-1, through protease-activated receptor-1 activation, triggers a hyperinflammatory response to M. tuberculosis infection. Flores-Villanueva et al [19] also reported that high levels of MCP-1 can inhibit the production of IL-12p40, which acts as a chemoattractant for macrophages and promotes the migration of bacterially stimulated dendritic cells [20] . Bone grafts were absorbed and internal fixation failed. 3a: At 2 weeks after surgery, bone grafts were well positioned. 3b: at 1 year after surgery, bone grafts were absorbed and internal fixation failed. Overexpression of MCP-1 can saturate target cells, causing them to lose sensitivity to the ligand, leading to changes in the MCP-1 concentration gradient and finally inhibiting the chemotactic response of monocytes [21] . MCP-1 overexpression can also up-regulate IL-4 expression, inducing the transformation of Th0 cells into Th2 cells, up-regulating the Th2 immune response and leading to further inhibition of the Th1 immune response in vivo [22] . These signaling pathways are likely to increase the risk of in vivo dissemination of M. tuberculosis and even lead to the recurrence of tuberculosis infection.
Yang's study [23] showed the same symptoms and a similar rate of disease recurrence. However, abscess accounted for 74.4% of all recurrent manifestations in that study. In our study the rate of abscess is only 27.3% in patients with recurrent disease. This is owing to a longer duration of preoperative and postoperative chemotherapy [24, 25] .Additionally, current studies on serum MCP-1 levels are performed mainly in patients with pulmonary tuberculosis. We report data on the correlation between serum MCP-1 levels and postoperative recurrence of spinal tuberculosis in the Chinese Han population. Related studies are underway. We believe that with the prolongation of the follow-up period, an increase in sample size and the development of animal experiments, the mechanism by which serum MCP-1 level influences postoperative complications in spinal tuberculosis will be further clarified. This will provide a novel strategy for preventing and treating postoperative complications in spinal tuberculosis.
Conclusions
In conclusion, our results suggest that the postoperative recurrence of spinal tuberculosis is likely to increase the serum level of MCP-1 in the Chinese Han population.
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